Abstract:Abstract Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses tumor progression, potentially displaying opposing effects on therapeutic outcomes. Chronic inflammation facilitates tumor progression and treatment resistance, whereas induction of acute inflammatory reactions often stimulates the maturation of dendritic cells (DCs) and antigen presentation, leading to anti-tumor immune responses. In addition, multiple signaling pathways, such as nuclear factor kappa B (NF-kB), Janus kinase/signal transducers and activators of transcription (JAK-STAT), toll-like receptor (TLR) pathways, cGAS/STING, and mitogen-activated protein kinase (MAPK); inflammatory factors, including cytokines (e.g., interleukin (IL), interferon (IFN), and tumor necrosis factor (TNF)-α), chemokines (e.g., C-C motif chemokine ligands (CCLs) and C-X-C motif chemokine ligands (CXCLs)), growth factors (e.g., vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β), and inflammasome; as well as inflammatory metabolites including prostaglandins, leukotrienes, thromboxane, and specialized proresolving mediators (SPM), have been identified as pivotal regulators of the initiation and resolution of inflammation. Nowadays, local irradiation, recombinant cytokines, neutralizing antibodies, small-molecule inhibitors, DC vaccines, oncolytic viruses, TLR agonists, and SPM have been developed to specifically modulate inflammation in cancer therapy, with some of these factors already undergoing clinical trials. Herein, we discuss the initiation and resolution of inflammation, the crosstalk between tumor development and inflammatory processes. We also highlight potential targets for harnessing inflammation in the treatment of cancer.

The Regulatory Role of PDE4B in the Progression of Inflammatory Function Study

Research Progress of Phosphodiesterase Inhibitors in Inflammatory Bowel Disease Treatment.

Progress in PDE4 Targeted Therapy for Inflammatory Diseases

Phosphodiesterase-4(PDE4) As a Target for Anti-Inflammatory Drug Discovery: Present and Prospect

Inhibitors of Phosphodiesterase As Cancer Therapeutics.

PKB/Akt-dependent regulation of inflammation in cancer

From Inflammation to Cancer: the Molecular Basis

The role of PDE4 in pulmonary inflammation and goblet cell hyperplasia in allergic rats.

Role of PDCD4 in Inflammation and Tumors: a Double-Edged Sword

Inflammation and tumor progression: signaling pathways and targeted intervention

The G-Protein Coupled Formyl Peptide Receptors and Their Role in the Progression of Digestive Tract Cancer

Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer

PDE4 inhibitors: potential protective effects in inflammation and vascular diseases

Targeting PDE4 as a promising therapeutic strategy in chronic ulcerative colitis through modulating mucosal homeostasis

Targeting the Inflammatory Pathways to Enhance Chemotherapy of Cancer

Prevention and treatment of cancer targeting chronic inflammation: research progress, potential agents, clinical studies and mechanisms

The functions and regulatory pathways of S100A8/A9 and its receptors in cancers

The Role of Purinergic P2X7 Receptor in Inflammation and Cancer: Novel Molecular Insights and Clinical Applications

Key Mediators of Oncogenesis and Progression in Pancreatic Ductal Adenocarcinoma (PDAC)

An overview of the regulatory role of annexin A1 in the tumor microenvironment and its prospective clinical application (Review)

MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer